231.54
                                            前日終値:
              $233.37
            開ける:
              $233.57
            24時間の取引高:
                336.89K
            Relative Volume:
              0.79
            時価総額:
                $9.03B
            収益:
              $1.24B
            当期純損益:
              $42.23M
            株価収益率:
              218.43
            EPS:
                1.06
            ネットキャッシュフロー:
                $150.33M
            1週間 パフォーマンス:
              -8.67%
            1か月 パフォーマンス:
              -7.99%
            6か月 パフォーマンス:
                -22.02%
            1年 パフォーマンス:
              +9.58%
            Penumbra Inc Stock (PEN) Company Profile
PEN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS | 
|---|---|---|---|---|---|---|
|   
                          
                                PEN
                            
                             Penumbra Inc | 231.54 | 9.10B | 1.24B | 42.23M | 150.33M | 1.06 | 
|   
                          
                                ABT
                            
                             Abbott Laboratories | 124.67 | 216.57B | 43.84B | 13.94B | 6.78B | 7.9979 | 
|   
                          
                                BSX
                            
                             Boston Scientific Corp | 100.57 | 148.62B | 19.35B | 2.78B | 3.49B | 1.8696 | 
|   
                          
                                SYK
                            
                             Stryker Corp | 368.98 | 141.30B | 23.82B | 2.92B | 4.02B | 7.5574 | 
|   
                          
                                MDT
                            
                             Medtronic Plc | 90.97 | 117.65B | 34.20B | 4.69B | 5.30B | 3.6218 | 
|   
                          
                                EW
                            
                             Edwards Lifesciences Corp | 83.48 | 48.55B | 5.69B | 1.41B | 577.90M | 6.9828 | 
Penumbra Inc Stock (PEN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 | 
|---|---|---|---|
| 2025-10-08 | アップグレード | Needham | Hold → Buy | 
| 2025-09-02 | 開始されました | Evercore ISI | Outperform | 
| 2025-03-14 | 開始されました | BofA Securities | Buy | 
| 2025-01-21 | 開始されました | UBS | Buy | 
| 2024-12-17 | 開始されました | Oppenheimer | Outperform | 
| 2024-12-11 | アップグレード | Wells Fargo | Equal Weight → Overweight | 
| 2024-09-18 | 開始されました | Stifel | Buy | 
| 2024-09-03 | 開始されました | Leerink Partners | Outperform | 
| 2024-07-31 | ダウングレード | Citigroup | Buy → Neutral | 
| 2024-07-31 | ダウングレード | Wells Fargo | Overweight → Equal Weight | 
| 2024-02-23 | ダウングレード | JP Morgan | Overweight → Neutral | 
| 2023-09-06 | 開始されました | Morgan Stanley | Equal-Weight | 
| 2023-07-19 | 開始されました | Robert W. Baird | Outperform | 
| 2023-03-29 | ダウングレード | Needham | Buy → Hold | 
| 2023-01-30 | 開始されました | Piper Sandler | Overweight | 
| 2022-11-04 | アップグレード | Citigroup | Neutral → Buy | 
| 2022-10-12 | 開始されました | Jefferies | Buy | 
| 2022-10-05 | ダウングレード | Citigroup | Buy → Neutral | 
| 2022-09-09 | アップグレード | Needham | Hold → Buy | 
| 2022-07-18 | 開始されました | RBC Capital Mkts | Outperform | 
| 2022-04-19 | 開始されました | Deutsche Bank | Buy | 
| 2022-03-08 | 開始されました | Needham | Hold | 
| 2021-09-16 | 開始されました | Truist | Buy | 
| 2021-06-04 | アップグレード | BTIG Research | Neutral → Buy | 
| 2020-12-16 | ダウングレード | BTIG Research | Buy → Neutral | 
| 2020-10-07 | 再開されました | Canaccord Genuity | Buy | 
| 2020-09-29 | 開始されました | BTIG Research | Buy | 
| 2020-09-08 | ダウングレード | BofA Securities | Buy → Neutral | 
| 2020-03-05 | 開始されました | Citigroup | Buy | 
| 2019-06-13 | 繰り返されました | BofA/Merrill | Buy | 
| 2019-05-30 | アップグレード | JP Morgan | Neutral → Overweight | 
| 2019-05-21 | 開始されました | William Blair | Outperform | 
| 2018-10-29 | 再開されました | BofA/Merrill | Buy | 
| 2018-10-08 | 開始されました | RBC Capital Mkts | Outperform | 
| 2018-02-21 | 開始されました | William Blair | Outperform | 
| 2018-01-02 | ダウングレード | JP Morgan | Overweight → Neutral | 
| 2015-11-30 | 繰り返されました | Canaccord Genuity | Buy | 
| 2015-10-13 | 開始されました | Wells Fargo | Outperform | 
                    すべてを表示
                     
                  
                Penumbra Inc (PEN) 最新ニュース
Is Penumbra Inc. stock a contrarian opportunityWeekly Trend Recap & Stock Portfolio Risk Control - newser.com
Is Penumbra Inc. stock undervalued vs historical averages2025 Trade Ideas & Real-Time Volume Analysis Alerts - newser.com
Why Penumbra Inc. stock fits value portfolios2025 Stock Rankings & High Yield Equity Trading Tips - newser.com
Is Penumbra Inc. stock a top hedge fund pickLong Setup & Weekly Return Optimization Plans - newser.com
Why Penumbra Inc. (0P8) stock is a strong buy call2025 Market Outlook & Long-Term Safe Return Strategies - newser.com
Is Penumbra Inc. (0P8) stock a momentum leaderJuly 2025 Technicals & Low Risk Entry Point Guides - newser.com
Is Penumbra’s Stock Still a Good Bet After a 7% Drop in the Past Month? - Yahoo Finance
Custom watchlist performance reports with Penumbra Inc.Entry Point & Verified Short-Term Plans - newser.com
Ischemic Neurological Interventional Medical Devices Market - openPR.com
Penumbra Enters Oversold Territory (PEN) - Nasdaq
Why Penumbra (PEN) Shares Are Falling Today - Yahoo Finance
Truist Financial Sticks to Its Buy Rating for Penumbra (PEN) - The Globe and Mail
How strong dollar benefits Penumbra Inc. stockJuly 2025 Retail & AI Based Buy/Sell Signal Reports - newser.com
Does Penumbra Inc. stock trade at a discount to peersMarket Growth Review & Free Reliable Trade Execution Plans - newser.com
Is Penumbra Inc. (0P8) stock a buy for dividend portfoliosPortfolio Gains Summary & High Accuracy Trade Signal Alerts - newser.com
Why Penumbra Inc. stock is a strong buy callJuly 2025 Action & Daily Profit Focused Stock Screening - newser.com
Landmark STORM-PE Randomized Controlled Trial Finds Computer Assisted Vacuum Thrombectomy (CAVT) with Anticoagulation Superior to Traditional Anticoagulation Treatment for Pulmonary Embolism - Lelezard
Will Penumbra Inc. stock attract ESG investorsJuly 2025 Selloffs & Consistent Income Trade Ideas - newser.com
Penumbra takes TCT by STORM - BioWorld MedTech
Penumbra Inc. Launches i-RISE Study to Enhance Stroke Treatment Insights - TipRanks
Is Penumbra Inc. (0P8) stock among top earnings playsJuly 2025 Update & Reliable Entry Point Trade Alerts - Fundação Cultural do Pará
Penumbra Inc.’s STRIKE-PE Study: A Game Changer for Pulmonary Embolism Treatment? - TipRanks
Penumbra, Inc. Experiences Revision in Its Stock Evaluation Amid Competitive Market Landscape - Markets Mojo
Penumbra Inc.’s STRIDE II Study: A Promising Update for Investors - TipRanks
Penumbra Inc.’s BOLT Study: A Game-Changer for Deep Vein Thrombosis Treatment? - TipRanks
Penumbra study backs mechanical thrombectomy for treating pulmonary embolism - MassDevice
Penumbra (PEN) Trial Shows Superior Results with Mechanical Thro - GuruFocus
Penumbra’s thrombectomy system shows superior results for PE patients - Investing.com
Penumbra’s thrombectomy system shows superior results for PE patients By Investing.com - Investing.com Nigeria
Penumbra (NYSE: PEN) RCT: CAVT 78.3% positive effect vs 51.9% with anticoagulation - Stock Titan
Deep Dive Into Penumbra Stock: Analyst Perspectives (13 Ratings) - Benzinga
Penumbra (PEN) Maintains Buy Rating with $326 Price Target by Ne - GuruFocus
PEN: BTIG Reiterates Buy Rating with $320 Price Target | PEN Sto - GuruFocus
Penumbra Inc (PEN) 財務データ
収益
当期純利益
現金流量
EPS
                大文字化:
                 
                  | 
                ボリューム (24 時間):
                 
            
         
                     
                             ストックスクリーナーアプリを入手
                    ストックスクリーナーアプリを入手